Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLR1A | O95602 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | CDC25C | P30307 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000585 | 0.90 | SMN1; SMN2 (0.42) | ALDH1A1ROCK1KDM4EMAPT | |
| SCHEMBL1997921 | 0.89 | CDC25B (0.44) | PDE4BALDH1A1RECQLKDM4EMAPT | |
| SCHEMBL5607208 | 0.89 | POLR1A (0.35) | POLR1AADORA1PDE4BALDH1A1KDM4E | |
| SCHEMBL2001500 | 0.88 | ALDH1A1 (0.39) | ALDH1A1RECQLKDM4EMAPTCDC25A | |
| SCHEMBL1999854 | 0.87 | NPC1 (0.39) | PDE4BALDH1A1RECQLMAPTAURKA | |
| SCHEMBL2001626 | 0.85 | TRPV1 (0.39) | ADORA1PDE4BADORA2BADORA2AALDH1A1 | |
| SCHEMBL1995464 | 0.84 | KMT2A (0.46) | ALDH1A1KDM4EMAPTL3MBTL1 | |
| SCHEMBL2000588 | 0.84 | TRPV1 (0.38) | ADORA1PDE4BADORA2BADORA2AALDH1A1 | |
| SCHEMBL1994571 | 0.83 | ADORA3 (0.40) | ADORA1PDE4BADORA2BADORA2AALDH1A1 | |
| SCHEMBL1999230 | 0.83 | AURKA (0.42) | ADORA1PDE4BADORA2BADORA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960383-B2 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL SA (ES) | 2011-06-14 | — | — | US | claimed |
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | ALMIRALL PRODESFARMA, SA (ES) | 2008-11-13 | — | — | US | claimed |
| EP-1758869-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123692-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | claimed |
| US-7960383-B2 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL SA (ES) | 2011-06-14 | — | — | US | disclosed |
| EP-1758869-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL SA (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | ALMIRALL PRODESFARMA, SA (ES) | 2008-11-13 | — | — | US | disclosed |
| EP-1758869-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123692-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | PDE12, PDE4A, PDE4B | POLR1A 1040/4885ADORA1 442/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.